Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris

About this trial

CAMPSIS is a preliminary feasibility study of the TheraOne medical device (IIb). TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability.

This study aims to evaluate the safety of cerebral sonication (TheraOne) in the management of patients with recurrent grade 4 glioma (wild-type IDH, technically resectable) or brain metastases originating from an extracranial solid tumor.

Patients enrolled in the study will undergo a single sonication session during a protocol visit and will be monitored for up to 30 days after the sonication through the various scheduled protocol visits.

Blood samples will be collected at the start of the study, during the sonication, and during the post-sonication follow-up visit for all patients enrolled in the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age: ≥18 years old.

Performance Status: Karnofsky Performance Score (KPS) ≥ 70%.

Patient with an expansive intra-cerebral tumor showing enhancement after gadolinium injection on MRI (T1-weighted images, with and without gadolinium contrast).

Recurrent High-Grade glioma (excluding prosthetic material), or a brain metastasis from extracranial solid primary.

Disqualifiers

Acute mass effect with ≥5 mm midline shift or basal cistern effacement.

Severe peritumoral edema causing acute intracranial hypertension or compression of critical structures.

Hemorrhagic transformation or necrosis with a high risk of rupture.

Significant tumor volume outside the treatment envelope.

Trial design

Design model

Single group

Treatments tested in this trial

  • Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne

    Procedure/Surgery

    TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability.

Treatment groups

6 Participants
are divided into 1 treatment group
Group A: Patients with recurrent grade 4 glioma or brain metastasis from an extracranial solid tumorExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Safety : evaluating the occurrence and severity of adverse events related to the sonication procedure

Time frame
Up to 14 days after the sonication

Secondary outcomes

1

Feasibility : completion rate of sonication phase

Time frame
Immediately after the procedure.
2

BBB permeability assessment by several MRI imaging at predefined timepoints.

Time frame
Up to 14 days after the sonication

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: